Phase 3 data at ASH 2018 highlighted investigational therapy in rare blood disorder

Myelodysplastic syndromes (MDS) often result in chronic anemia, which is associated with poor quality of life for patients — and there have been no new U.S. FDA-approved therapies for the treatment of MDS in more than 10 years. Findings from a phase 3 study of an investigational therapy in patients with MDS were presented during the plenary scientific session at the American Society of Hematology (ASH) 2018 Annual Meeting.